Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.62 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.55 |
| ▸ | TDP2 | O95551 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201259 | 1.00 | PARP1 (0.62) | PARP1PARP10PBRM1TDP2ATM | |
| SCHEMBL30934632 | 0.91 | PARP1 (0.57) | PARP1PARP10PBRM1TDP2ATM | |
| SCHEMBL6247902 | 0.85 | TDP2 (0.55) | PARP1PARP10PBRM1TDP2MAOB | |
| SCHEMBL2388879 | 0.84 | CASP1 (0.55) | PARP1PARP10TDP2ATMNOTUM | |
| SCHEMBL31143658 | 0.80 | PBRM1 (0.55) | PARP1PARP10PBRM1ALDH1A1L3MBTL1 | |
| SCHEMBL6207175 | 0.80 | PBRM1 (0.55) | PARP1PARP10PBRM1ALDH1A1L3MBTL1 | |
| SCHEMBL1986133 | 0.78 | PARP1 (0.47) | PARP1PARP10PBRM1TDP2ATM | |
| SCHEMBL29235229 | 0.78 | PARP1 (0.47) | PARP1PARP10TDP2ATMNOTUM | |
| SCHEMBL31026824 | 0.78 | PARP1 (0.47) | PARP1PARP10TDP2ATMNOTUM | |
| SCHEMBL15467947 | 0.78 | PARP1 (0.51) | PARP1PARP10TDP2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240368001-A1 | SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-11-07 | — | — | US | disclosed |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4384503-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11987506-B2 | Salt recovery solution and processes of use thereof | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-05-21 | — | — | US | disclosed |
| US-7678798-B2 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION | 2009-08-06 | — | — | US | disclosed |
| EP-1734966-A4 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| CN-1968698-A | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE SAN DIEGO INC (US) | 2007-05-23 | — | — | CN | disclosed |
| EP-1734966-A2 | PIPERIZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | Incyte Corporation (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | INCYTE CORPORATION | 2005-11-24 | — | — | US | disclosed |
| WO-2005101838-A2 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | INCYTE CORPORATION (US) | 2005-10-27 | — | — | WO | disclosed |
| US-4132737-A | ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | PARP1 176/4885PARP10 232/4885PBRM1 70/4885 |
| US-20240239766-A1 | 3-AMINO PIPERIDYL SODIUM CHANNEL INHIBITORS | CACNA1E, TRPV1, SCN3A | PARP1 889/4885PARP10 454/4885PBRM1 1930/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | PARP1 233/4885PARP10 136/4885PBRM1 240/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | PARP1 644/4885PARP10 1129/4885PBRM1 2806/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | PARP1 233/4885PARP10 136/4885PBRM1 240/4885 |
| US-20050261310-A1 | Piperazinylpiperidine derivatives as chemokine receptor antagonists | CCR5, CCR2, CXCR5 | PARP1 1470/4885PARP10 1260/4885PBRM1 3015/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | PARP1 999/4885PARP10 1592/4885PBRM1 3008/4885 |
| US-20090197887-A1 | PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | CCR5, CCR2, CXCR5 | PARP1 1470/4885PARP10 1260/4885PBRM1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.